Comparison of in vitro translated HPV-16 E7 protein with GST-fusion HPV-16 E7 protein as serologic markers in patients with cervical cancer

The purpose of the study is to investigate in vitro translated HPV-16 E7 protein and GST-fusion HPV-16 E7 protein as serologic markers in females with cervical cancer. The sera of 39% (39/100) of patients with cervical cancer were RIPA positive for in vitro translated HPV-16 E7 protein and the sera of 29% (29/100) of females with cervical cancer were ELISA positive far HPV-16 GST-fusion E7 protein. The positivities for in vitro translated HPV-16 E7 protein in cervical cancers were 14% (7/49) in stage I, 59% (26/44) in stage II, and 86% (6/7) in stage III/IV, thus significantly correlating with advancing stage of the disease (P < 0.01). These data suggest that many patients with cervical neoplasia generate a positive antibody response to HPV-16 E7 proteins. The antibody positives to in vitro translated HPV-16 E7 protein increase with advancing clinical stage of disease. These HPV-16 E7 proteins might be a disease-specific markers which could be useful in adjunctive diagnostic assay of HPV-related cervical neoplasia.